Table 3.
Study 2 (prospective) results of serology for paired sera (S1, S2) for the Rickettsia spp. seroreactive patients and for Borrelia spp.
| No. | Age/ sex | Duration of symptoms (days) | S1 | S2 | Weeks/S1–S2 | Borrelias IgG/IgM (S1/S2) | Treatment | Tick bite | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IgG | IgM | IgG | IgM | |||||||
| Facial palsy | ||||||||||
| P1 | 51/F | 24 | <64 | 512 | 64 | 256 | 20 | neg/neg | P | ND |
| P2 | 53/F | 6 | 64 | 128 | 256 | 64 | 6 | neg/neg | P, DC | ND |
| P3 | 47/M | 4 | <64 | <64 | 64 | <64 | 20 | ND/neg | P | ND |
| P4 | 68/F | 3 | <64 | <64 | 64 | <64 | 5 | neg/neg | LT | ND |
| P5 | 55/F | 5 | 64 | 128 | NA | NA | neg/neg | P, AV | N | |
| P6 | 57/F | 4 | <64 | 64 | <64 | <64 | 4 | neg/neg | P | ND |
| P7 | 78/F | 3 | <64 | 64 | <64 | <64 | 7 | neg/neg | LT | ND |
| P8 | 23/F | 5 | 64 | 512 | 64 | 256 | 4 | neg/neg | P, DC | ND |
| P9 | 55/F | 3 | <64 | 256 | <64 | 256 | 3 | neg/neg | LT | ND |
| P10 | 30/F | 4 | 64 | 256 | NA | NA | ND/neg | P | ND | |
| P11 | 60/F | 5 | 64 | 256 | <64 | 128 | 4 | neg/neg | DC | ND |
| P12 | 35/F | 5 | 256 | 512 | 256 | 256 | 6 | ND/neg | P, DC | ND |
| P13 | 46/F | 3 | <64 | <64 | <64 | 128 | 7 | ND/neg | P | ND |
| P14 | 39/M | 3 | <64 | 64 | 128 | 256 | 5 | ND/neg | DC | ND |
| P15 | 47/M | 16 | 256 | <64 | 128 | 64 | 5 | neg/neg | P | ND |
| P16 | 19/M | 3 | <64 | 128 | NA | NA | ND/neg | P | ND | |
| Sudden deafness | ||||||||||
| P17 | 65/F | 4 | <64 | 128 | 64 | 128 | 3 | neg/neg | P, DC | ND |
| P18 | 66/F | 5 | <64 | 512 | 64 | 128 | 4 | neg/neg | DC | ND |
| P19 | 57/M | 3 | <64 | <64 | 64 | <64 | 4 | neg/neg | P | ND |
| P20 | 47/M | 4 | <64 | 128 | <64 | 128 | 22 | neg/neg | P | ND |
| P21 | 41/F | 4 | <64 | 128 | NA | NA | neg/neg | ND | ||
| P22 | 52/M | 3 | <64 | <64 | 256 | 128 | 23 | neg/neg | P, AV | ND |
| P23 | 72/M | 2 | <64 | 256 | 512 | 512 | 20 | ND/neg | P, | ND |
| P24 | 52/M | 6 | <64 | 128 | NA | NA | neg/neg | P, AV | ND | |
| P25 | 74/F | 8 | <64 | 256 | NA | NA | G+/M−/neg | ND | ||
| P26 | 37/M | 2 | <64 | 128 | <64 | 64 | 7 | neg/neg | DC | ND |
| P27 | 35/M | 1 | <64 | 256 | 64 | 64 | 9 | ND/neg | ND | |
| P28 | 72/M | 2 | <64 | 256 | 128 | 128 | 5 | neg/neg | P, DC | ND |
| P29 | 52/M | 16 | 64 | 64 | 256 | <64 | 9 | neg/neg | P | ND |
| P30 | 63/M | 3 | <64 | 256 | 128 | 128 | 10 | neg/neg | P, DC | ND |
| P31 | 31/M | 6 | <64 | 64 | <64 | <64 | 4 | neg/neg | P | ND |
| P32 | 70/M | 3 | <64 | <64 | 64 | <64 | 5 | neg/neg | ND | |
| P33 | 69/M | 4 | <64 | <64 | 128 | 128 | 5 | neg/neg | P | ND |
| P34 | 46/M | 2 | <64 | <64 | 64 | 64 | 24 | neg/neg | P, AV | ND |
| P35 | 51/M | 320 | <64 | <64 | <64 | 128 | 10 | neg/neg | P | ND |
| P36 | 68/F | 6 | <64 | <64 | 64 | <64 | 5 | neg/neg | ND | |
| P37 | 81/M | 25 | <64 | 128 | <64 | 128 | 4 | neg(S2) | ND | |
| P38 | 82/F | 8 | <64 | <64 | 128 | 128 | 9 | neg/neg | P, DC | ND |
| P39 | 74/M | 6 | <64 | <64 | 64 | 64 | 5 | neg/neg | AV | ND |
| P40 | 43/F | 4 | <64 | <64 | <64 | 128 | 12 | neg/neg | P | ND |
| P41 | 68/M | 4 | 64 | <64 | 128 | 256 | 7 | neg/neg | ND | |
| P42 | 63/F | 3 | 64 | 128 | 64 | 128 | 4 | neg/neg | ND | |
| P43 | 45/F | 4 | <64 | <64 | <64 | 256 | 6 | neg/neg | P | ND |
| P44 | 71/M | 5 | <64 | <64 | 512 | 512 | 11 | neg/neg | P | ND |
| P45 | 57/M | 3 | <64 | <64 | <64 | 256 | 11 | neg/neg | P, AV | ND |
ND, not done; P1–P45, prospective patient number 1 to 45. P, penicillin; DC, doxycycline; LT, local treatment; AV, antiviral; neg, negative.